Alnylam Pharmaceuticals, Inc. (ALNY) Misses Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $248.68 +0.47%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $9.36 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald After Management Chat
- Premarket movers: Oracle surges on AI growth, ACV auctions jumps on $1.9B deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
